Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment.

Research output: Contribution to journalArticle

Abstract

Tasquinimod (a quinoline-3-carboxyamide) is a small molecule immunotherapy with demonstrated effects on the tumor microenvironment (TME) involving immunomodulation, anti-angiogenesis and inhibition of metastasis. A target molecule of tasquinimod is the inflammatory protein S100A9 which has been shown to affect the accumulation and function of suppressive myeloid cell subsets in tumors. Given the major impact of myeloid cells to the tumor microenvironment, manipulation of this cell compartment is a desirable goal in cancer therapeutics.

Details

Authors
  • Anders Olsson
  • Jessica Nakhlé
  • Anette Sundstedt
  • Pascale Plas
  • Anne-Laure Bauchet
  • Valérie Pierron
  • Luce Bruetschy
  • Adnan Deronic
  • Marie Törngren
  • David Liberg
  • Fabien Schmidlin
  • Tomas Leanderson
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cell and Molecular Biology
Original languageEnglish
Article number53
JournalJournal for ImmunoTherapy of Cancer
Volume3
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes